A recent article published on Pharmaceutical Executive looks at how health technology assessment is playing out in the U.S., and suggests that the number of organizations performing these assessments will “grow in number.”
The authors write, however, that the Institute for Clinical and Economic Review (ICER) will “remain the most prominent (Pharmaceutical Value Assessment) organization in the near-term.”
“U.S. decision-makers need guidance about what policies will ensure that value assessments for the U.S. market will support access to today’s innovative therapies for current patients and a robust ongoing flow of innovation to serve the needs of future generations,” the article states.
To read the full article, click here.